Provided by Tiger Trade Technology Pte. Ltd.

Insmed

153.32
+8.025.52%
Post-market: 153.00-0.3200-0.21%19:56 EDT
Volume:4.96M
Turnover:760.33M
Market Cap:33.05B
PE:-23.88
High:155.20
Open:150.98
Low:149.35
Close:145.30
52wk High:212.75
52wk Low:60.40
Shares:215.55M
Float Shares:193.00M
Volume Ratio:1.67
T/O Rate:2.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.4200
EPS(LYR):-6.4200
ROE:-249.28%
ROA:-28.99%
PB:44.72
PE(LYR):-23.88

Loading ...

Insmed Inc - to File Supplemental Nda for Arikayce With FDA and Submit Data to Pmda Japan in H2 2026

THOMSON REUTERS
·
Mar 23

Insmed Announces Positive Topline Results From Phase 3B Encore Study of Arikayce® (Amikacin Liposome Inhalation Suspension) in Patients With Mac Lung Disease

THOMSON REUTERS
·
Mar 23

U.S. RESEARCH ROUNDUP- ArriVent Biopharma, Aveanna Healthcare Holdings, EQT

Reuters
·
Mar 23

Brinsupri Launch Gives Insmed A New Respiratory Revenue Pillar

Simply Wall St.
·
Mar 19

Analysts Offer Insights on Healthcare Companies: Insmed (INSM) and Ansell (OtherANSLF)

TIPRANKS
·
Mar 19

Insmed Coverage Assumed by Jefferies at Buy

Dow Jones
·
Mar 17

Insmed assumed with a Buy at Jefferies

TIPRANKS
·
Mar 16

U.S. RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Cogent Biosciences, Summit Therapeutics

Reuters
·
Mar 16

Insmed Chair and CEO William Lewis Disposes of Common Shares

Reuters
·
Mar 06

Insmed Grants Inducement Equity Awards to 85 New Hires

Reuters
·
Mar 05

Insmed (INSM) Receives a Buy from Evercore ISI

TIPRANKS
·
Feb 26

Insmed Chief Legal Officer Michael Alexander Smith Disposes of Common Shares

Reuters
·
Feb 26

BUZZ - Nasdaq top and bottom performing stocks at about 02:45 p.m. EST on 2026-02-25

Reuters
·
Feb 26

Insmed Chair and CEO William Lewis reports disposal of common shares

Reuters
·
Feb 24

Pre-Bell | Wall St Futures Dip; Novo Nordisk Sinks 15%; Eli Lilly Gains 3%; Domino’s Pizza Jumps 5%; Arcellx Soars 78%

Tiger Newspress
·
Feb 23

H.C. Wainwright Remains a Buy on Insmed (INSM)

TIPRANKS
·
Feb 23

Insmed Gets UK Marketing Authorization for Non-Cystic Fibrosis Bronchiectasis Treatment

MT Newswires Live
·
Feb 23

BRIEF-MHRA Says Licensed Brensocatib as First Drug for Non-Cystic Fibrosis Bronchiectasis in Patients Aged 12+

Reuters
·
Feb 23

Mhra: Brensocatib Licensed as First Medicine Specifically Designed to Treat Non-Cystic Fibrosis Bronchiectasis in Patients 12 Years and Older

THOMSON REUTERS
·
Feb 23

Analysts Offer Insights on Healthcare Companies: Insmed (INSM) and 10x Genomics (TXG)

TIPRANKS
·
Feb 22